3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
17
Ovarian Neoplasms
16
Fallopian Tube Neoplasms
12
Neoplasm Metastasis
10
Triple Negative Breast Neoplasms
7
Prostatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
6
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Neuroendocrine Tumors
3
Metastatic Castration-resistant Prostate Cancer
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Sarcoma
2
Recurrence
2
Pheochromocytoma
2
Paraganglioma
2
Osteosarcoma
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Interventions
Cisplatin
11
pembrolizumab
10
Carboplatin
7
Radiotherapy
6
Cetuximab
6
Docetaxel
5
Surveys and Questionnaires
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Cyclophosphamide
3
fludarabine
2
cemiplimab
2
atezolizumab
2
aldesleukin
2
Surgical Procedures, Operative
2
Standard of Care
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Fluorouracil
2
Drug Therapy
2
vistusertib
1
toripalimab
1
sitravatinib
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
lenvatinib
1
fludarabine phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
olaparib
×
90 days
×
Clear all
NCT02308072
2026-05-22
ORCA-2
University College, London
Phase 1
Completed
16 enrolled